Video

Dr Zahra Mahmoudjafari Previews CAR T Therapies Coming Down the Pipeline

Zahra Mahmoudjafari, PharmD, BCOP, clinical pharmacy manager at the University of Kansas Health System, catalogues the chimeric antigen receptor T-cell (CAR T) therapies that are coming down the pipeline.

Zahra Mahmoudjafari, PharmD, BCOP, clinical pharmacy manager at the University of Kansas Health System, catalogues the chimeric antigen receptor T-cell (CAR T) therapies that are coming down the pipeline.

Transcript

What CAR T therapies do you see coming down the pipeline and how do they differ from each other?

That's a loaded question; there's a lot. For the currently approved products, we're learning to use them earlier in lines of care. For the diffuse large B-cell lymphoma population, those indications, and second-line therapy should be coming anytime in the next week to the next couple of months.

Then, we are looking at expanding indications to larger disease states. Obviously, we've had a lot of great approvals with the multiple myeloma products. That recent approval was just on February 28, so I think myeloma is good for a little bit.

In terms of CAR T specifically, for immune effector cells, the bispecifics are the next thing that we're really excited about. We're also looking at allogeneic CAR T products, which are off the shelf, which would really significantly decrease the manufacturing time that we are challenged with at this point.

Related Videos
Shawn Griffin, MD, sitting for a video interview
Christine Funke, MD
John Michael O'Brien, PharmD, MPH
Kathi Henson, MBA, sitting for a video interview
Mike Fazio, Navista, Cardinal Health
Dr Mingyang Song
Fran Gregory, PharmD, MBA, sitting for a video interview
Casey Koch, PharmD, sitting for a video interview
Dr K. Vish Viswanath
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo